BACKGROUND: Accuracy of sentinel lymph node biopsy (SLNB) and rate of axillary recurrence in multicentric/multifocal (MC/MF) breast cancer are reported. METHODS: From 1999 to 2006, 93 patients with MC/MF breast cancer underwent SLNB; 41 underwent axillary lymph node dissection regardless of SLN pathology (group 1), and 52 underwent axillary lymph node dissection only if an SLN was positive (group 2). Patient demographics, SLN techniques, and pathology were recorded. RESULTS: There were no differences between the 2 groups with respect to patient age; tumor size, grade, stage, and histology; or method of SLN detection. The incidence of axillary metastasis was greater in group 1 patients (68%) compared with group 2 patients (12%) (P < .01). In group 1, the sensitivity and specificity of SLNB were 93% and 100%, respectively, with a false-negative rate of 7%. None of the 52 patients in group 2 experienced axillary recurrence (median follow-up 4.8 years). CONCLUSIONS: The accuracy of SLNB in MC/MF breast cancer is comparable with that observed in unifocal breast cancer. Despite a lower rate of SLN positivity in patients undergoing SLNB only, axillary recurrence was not observed.
BACKGROUND: Accuracy of sentinel lymph node biopsy (SLNB) and rate of axillary recurrence in multicentric/multifocal (MC/MF) breast cancer are reported. METHODS: From 1999 to 2006, 93 patients with MC/MF breast cancer underwent SLNB; 41 underwent axillary lymph node dissection regardless of SLN pathology (group 1), and 52 underwent axillary lymph node dissection only if an SLN was positive (group 2). Patient demographics, SLN techniques, and pathology were recorded. RESULTS: There were no differences between the 2 groups with respect to patient age; tumor size, grade, stage, and histology; or method of SLN detection. The incidence of axillary metastasis was greater in group 1 patients (68%) compared with group 2 patients (12%) (P < .01). In group 1, the sensitivity and specificity of SLNB were 93% and 100%, respectively, with a false-negative rate of 7%. None of the 52 patients in group 2 experienced axillary recurrence (median follow-up 4.8 years). CONCLUSIONS: The accuracy of SLNB in MC/MF breast cancer is comparable with that observed in unifocal breast cancer. Despite a lower rate of SLN positivity in patients undergoing SLNB only, axillary recurrence was not observed.
Authors: O Gentilini; G Trifirò; J Soteldo; A Luini; M Intra; V Galimberti; P Veronesi; L Silva; S Gandini; G Paganelli; U Veronesi Journal: Eur J Surg Oncol Date: 2006-04-03 Impact factor: 4.424
Authors: Todd M Tuttle; Marybeth Colbert; Robert Christensen; Kevin J Ose; Thomas Jones; Robert Wetherille; Joel Friedman; Karen Swenson; Kelly M McMasters Journal: Ann Surg Oncol Date: 2002 Jan-Feb Impact factor: 5.344
Authors: U Veronesi; G Paganelli; G Viale; V Galimberti; A Luini; S Zurrida; C Robertson; V Sacchini; P Veronesi; E Orvieto; C De Cicco; M Intra; G Tosi; D Scarpa Journal: J Natl Cancer Inst Date: 1999-02-17 Impact factor: 13.506
Authors: K M McMasters; T M Tuttle; D J Carlson; C M Brown; R D Noyes; R L Glaser; D J Vennekotter; P S Turk; P S Tate; A Sardi; P B Cerrito; M J Edwards Journal: J Clin Oncol Date: 2000-07 Impact factor: 44.544
Authors: G Vlastos; I T Rubio; N Q Mirza; L A Newman; R Aurora; J Alderfer; A U Buzdar; S E Singletary Journal: Ann Surg Oncol Date: 2000-09 Impact factor: 5.344
Authors: David N Krag; Stewart J Anderson; Thomas B Julian; Ann M Brown; Seth P Harlow; Takamaru Ashikaga; Donald L Weaver; Barbara J Miller; Lynne M Jalovec; Thomas G Frazier; R Dirk Noyes; André Robidoux; Hugh M C Scarth; Denise M Mammolito; David R McCready; Eleftherios P Mamounas; Joseph P Costantino; Norman Wolmark Journal: Lancet Oncol Date: 2007-10 Impact factor: 41.316
Authors: Eleni Tousimis; Kimberly J Van Zee; Jane V Fey; Laura Weldon Hoque; Lee K Tan; Hiram S Cody; Patrick I Borgen; Leslie L Montgomery Journal: J Am Coll Surg Date: 2003-10 Impact factor: 6.113